POSITION
Co-Lead
BOARD
BOD Member until December 2011
EXIT
Acquired by Alexion in December 2011
Headquartered in Montreal, Enobia Pharma was a privately held company founded in 1997. The company’s mission was to develop therapies for the treatment of serious neglected diseases affecting the skeletal system, for which no treatment exists. These diseases are the result of an imbalance of specific enzymes that affect bone growth. Using a proprietary bone-targeted form of recombinant alkaline phosphatase, the first program of Enobia was the development of compounds to treat hypophosphatasia. Enobia was acquired by Alexion in December 2011. Henceforth, the compound has reached commercial status.